Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Enfusion Announces Fourth Quarter 2023 Results and Full Year 2023 Results

Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading software-as-a-service (SaaS) platform for investment managers, has posted its fourth quarter and full year 2023 financial results as part of its 4Q 2023 Shareholder Letter which can be viewed here or by navigating to the Financials section of its Investor Relations website which can be found at http://ir.enfusion.com.

4Q23 Earnings Conference Call

Management will host a conference call today, March 12, 2024, at 8:30 am ET to discuss the results.

To pre-register for the live teleconference of the fourth quarter earnings call, please use this link. To access this call, dial (888) 596-4144. The conference ID number is 9652536.

The earnings conference call will also be webcast live. Due to high call volumes, we urge interested parties to join the live webcast of the event through Enfusion’s website at https://ir.enfusion.com/events-and-presentations/events/default.aspx.

About Enfusion

Enfusion's investment management software-as-a-service (SaaS) platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one system. Through its software, analytics, and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence and collaboration boosting agility and powering growth. Enfusion partners with over 850 investment managers from 9 global offices spanning four continents.

Source: Enfusion, Inc.

Source Code: ENFN-IR

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.